MSLE 6-K: Fda approval

Filed with the SEC on · accession 0001171843-26-007206

MSLE filed a 6-K (foreign company report) with the SEC on Nov 6, 2026. Following FDA feedback, Satellos Bioscience changed the primary efficacy endpoint of its Phase 2 BASECAMP pediatric DMD trial for forazapadin from dynamometry to MRI-measured vastus lateralis fat fraction, which may support a potential accelerated approval pathway.

Summary of the filing

Following FDA feedback, Satellos Bioscience changed the primary efficacy endpoint of its Phase 2 BASECAMP pediatric DMD trial for forazapadin from dynamometry to MRI-measured vastus lateralis fat fraction, which may support a potential accelerated approval pathway. Topline 12-week placebo-controlled data are expected in Q1 2027.

Key details

Mean reduction in MRI-measured biceps brachii muscle fat fraction in TRAILHEAD (percentage points)N/A 4
Baseline biceps brachii fat fraction in TRAILHEADN/A 50
Day 140 biceps brachii fat fraction in TRAILHEADN/A 46
Number of participants in BASECAMP Phase 2 trialN/A 53
IssuerSatellos Bioscience Inc.
Regulator providing feedbackU.S. Food and Drug Administration
Co-founder and chief executive officerFrank Gleeson
Chief medical officerWildon Farwell

✦ Ask GOAX AI about this filing — what it means for MSLE, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for MSLE?

Click here

Frequently asked questions

What did MSLE file with the SEC on Nov 6, 2026?

MSLE filed a 6-K (Fda approval). Following FDA feedback, Satellos Bioscience changed the primary efficacy endpoint of its Phase 2 BASECAMP pediatric DMD trial for forazapadin from dynamometry to MRI-measured vastus lateralis fat fraction, which may support a potential accelerated approval pathway. Topline 12-week placebo-controlled data are expected in Q1 2027.

What does a fda approval mean for MSLE stock?

For a small biotech one drug can be most of the company’s value. Approval opens sales; a rejection (complete response letter) can delay it by years.

How do I read a 6-K?

How foreign companies listed in the US report news and events — like an 8-K for them. Look at the exhibit names: "results", "resign", "notice" tell you the topic. Many 6-Ks are routine (meeting notices); results and leadership changes matter most.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 6-K (foreign company report): How foreign companies listed in the US report news and events — like an 8-K for them.

Other MSLE SEC filings

Get alerts when MSLE files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days